Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)

• Company Description    Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif. Number of Employees: 702

• Price / Volume Information    Yesterday's Closing Price: $4.01 Daily Weekly Monthly 20 Day Moving Average: 1,019,209 shares Shares Outstanding: 129.14 (millions) Market Capitalization: $517.86 (millions) Beta: 1.22 52 Week High: $6.18 52 Week Low: $2.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.87% -10.47% 12 Week -8.86% -15.75% Year To Date -20.59% -27.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47215 Lakeview Blvd. - Fremont,CA 94538 USA ph: 877-922-9835 fax: - investors@cytekbio.com https://cytekbio.com

• General Corporate Information    Officers Wenbin Jiang - President and Chief Executive Officer William McCombe - Chief Financial Officer Ming Yan - Chief Technology Officer and Director Jack Ball - Director Richard Chin - Director Peer Information Cytek Biosciences, Inc. (CORR.) Cytek Biosciences, Inc. (RSPI) Cytek Biosciences, Inc. (CGXP) Cytek Biosciences, Inc. (BGEN) Cytek Biosciences, Inc. (GTBP) Cytek Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23285D109 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 129.14 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $517.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.58 Price/Cash Flow: - Price / Sales: 2.54 EPS Growth vs. Year Ago Period: -66.67% vs. Previous Quarter: -275.00% Sales Growth vs. Year Ago Period: 6.46% vs. Previous Quarter: -28.98% ROE 03/31/26 - -10.07 12/31/25 - -7.70 09/30/25 - -3.35 ROA 03/31/26 - -7.56 12/31/25 - -5.89 09/30/25 - -2.60 Current Ratio 03/31/26 - 4.69 12/31/25 - 5.04 09/30/25 - 5.17 Quick Ratio 03/31/26 - 4.07 12/31/25 - 4.42 09/30/25 - 4.48 Operating Margin 03/31/26 - -17.58 12/31/25 - -14.11 09/30/25 - -6.51 Net Margin 03/31/26 - -36.25 12/31/25 - -33.02 09/30/25 - -6.51 Pre-Tax Margin 03/31/26 - -17.61 12/31/25 - -14.81 09/30/25 - -7.87 Book Value 03/31/26 - 2.54 12/31/25 - 2.67 09/30/25 - 2.96 Inventory Turnover 03/31/26 - 1.98 12/31/25 - 1.99 09/30/25 - 1.92 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.12 12/31/25 - 0.15 09/30/25 - 0.17

Powered by Zacks Investment Research ©